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The αvβ6 integrin plays a key role in the activation of transforming growth factor-β (TGFβ), a
pro-fibrotic mediator that is pivotal to the development of idiopathic pulmonary fibrosis (IPF).
We identified a selective small molecule αvβ6 RGD-mimetic, GSK3008348, and profiled it in
a range of disease relevant pre-clinical systems. To understand the relationship between
target engagement and inhibition of fibrosis, we measured pharmacodynamic and disease-
related end points. Here, we report, GSK3008348 binds to αvβ6 with high affinity in human
IPF lung and reduces downstream pro-fibrotic TGFβ signaling to normal levels. In human lung
epithelial cells, GSK3008348 induces rapid internalization and lysosomal degradation of the
αvβ6 integrin. In the murine bleomycin-induced lung fibrosis model, GSK3008348 engages
αvβ6, induces prolonged inhibition of TGFβ signaling and reduces lung collagen deposition
and serum C3M, a marker of IPF disease progression. These studies highlight the potential of
inhaled GSK3008348 as an anti-fibrotic therapy.
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F ibrosis is the formation of scar tissue and occurs due toinjury or long-term inflammation followed by abnormalwound healing. It is a leading cause of morbidity and
mortality in a range of diseases1. Fibrotic disorders include
idiopathic pulmonary fibrosis (IPF), the most common of the
idiopathic interstitial pneumonias, for which there are currently
limited pharmacological therapeutic options2. The global inci-
dence of IPF is increasing and is conservatively estimated to be
3–9 people per 100,000 per year3. Recently, there has been
international approval of pirfenidone and nintedanib, drugs that
slow disease progression in IPF4–7. However, the failure of pir-
fenidone and nintedanib to halt or reverse disease progression,
and their unclear mechanisms of action make them sub-optimal
treatments. Furthermore, their side-effect profiles lead to con-
siderable patient tolerability issues7,8. Existing therapies are oral
and one of the areas yet to be fully explored in IPF is the potential
for the inhaled route of delivery directly to the fibrotic lung. By
minimizing the drug dose and systemic exposure, topical delivery
to the lungs could offer an improved safety profile compared with
systemically bioavailable treatments.
The alpha-v beta-6 (αvβ6) integrin is a member of the arginyl-
glycinyl-aspartic acid (RGD) sub-family of the heterodimeric,
transmembrane glycoprotein receptors9. The primary function of
the αvβ6 integrin is to activate the key pro-fibrotic mediator,
transforming growth factor-β1 (TGFβ1)10,11. The αvβ6 integrin is
upregulated in patients with IPF and the level of expression
appears to be linked to prognosis12,13, making this integrin not
only a potential biomarker of disease progression, but also an
attractive therapeutic target. The interest in αv integrins as
therapeutic targets in fibrosis has increased significantly14, with
many pharmaceutical companies beginning multiple drug dis-
covery initiatives within this space. This has been led by the
development of the αvβ6 monoclonal antibody STX100 (known
pre-clinically as 3G9 and clinically as BG00011)12 that has
recently completed a phase II trial for IPF15. The extensive target
validation of αvβ6 within IPF, other types of organ fibrosis16,17
and cancer18, combined with the significant renewed interest in
the RGD integrins by academic and industrial groups14,19, has
resulted in a renaissance for integrins as drug targets.
To improve the probability of success and enable robust testing
of early pre-clinical efficacy, a bespoke, IPF-specific, inhaled drug
discovery effort targeting the αvβ6 integrin was carried out. A
clear path from pre-clinical to early clinical studies was designed
to ensure target engagement could be measured and associated
with functional, innovative pharmacodynamic (PD), and disease
end points, including imaging and soluble biomarkers to increase
the chance of successful translation into clinical trials. In this
study, the pre-clinical characterization of an inhaled first in class
clinical candidate, GSK3008348, is described. These studies
demonstrate that GSK3008348 binds to the αvβ6 integrin with
high affinity and selectivity in human fibrotic lung tissue and
isolated lung epithelial cells. GSK3008348 inhibits TGFβ activa-
tion and reduces downstream pro-fibrotic signaling. In the
murine bleomycin-induced model of lung fibrosis, GSK3008348
engages αvβ6 integrins, inhibits the activation of TGFβ with a
prolonged duration of action, and reduces lung fibrotic end
points including collagen deposition and serum C3M levels, a
clinically relevant marker of IPF disease progression. These stu-
dies describe an exemplar pathway for the development of an
inhaled αvβ6 integrin inhibitor, highlighting the potential of
inhaled GSK3008348 as an anti-fibrotic therapy.
Results
Physico-chemical and pharmacokinetic profile of GSK3008348.
GSK3008348 is an RGD-mimetic with the tetrahydronaphthyridine
and arylbutanoic acid motifs replacing the arginine and aspartic acid
residues, respectively (Fig. 1a). Molecular modeling was used to aid
the structure activity relationships around GSK3008348 based on a
homology model developed using the closed form of αvβ3 X-ray
structure 1L5G20 as a template. Docked GSK3008348 (orange)
predicts binding site electrostatic interactions between the 1,8-tet-
rahydronaphthyridine and αv-Asp218, coordination of the car-
boxylic acid motif with a manganese ion in the metal ion dependent
GSK3008348
HCl
lle200
lle236 Ala234
Ala143
Thr238
Asp218
Ser199
Lys187
Solution Solubility
Saline pH 4–7, pH 7.5 >55, 31 mg/ml
SLF pH 6.6 >55 mg/ml
Rat pharmacokinetics (inhaled)
Tmax 0.2 h
Bioavailability 40–63 %
Permeability (passive) Lung binding (human)
20 nm/s 89.2 %
a b
c
Fig. 1 Structure, solubility, and pharmacokinetic properties of GSK3008348. a The chemical structure of GSK3008348 with full chemical name: (S)-3-
(3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)-4-(R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid). b Docked
GSK3008348 (orange) in a homology model of αvβ6 based on αvβ3 X-ray (1L5G) composed of α-subunit (magenta) and β-subunit (gray). c Solubility and
key pharmacokinetic properties for GSK3008348 are also shown. SLF, simulated lung fluid.
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adhesion site and an H-bond with Ala143 (Fig. 1b). The dimethyl-
pyrazolo phenyl moiety binds in proximity to β6 subunit residues
Ala143, Lys187, Ser199, Ile200, Ala234, and Ile236 in the specificity
binding loop (SDL) region.
Crystalline GSK3008348 hydrochloride was prepared in seven
linear steps from commercially available starting materials with
the key synthetic step featuring a stereoselective introduction of
the pyrazoloaryl ring via a rhodium catalyzed boronic acid
addition to a crotonate21. The physico-chemical properties are
commensurate with inhaled dosing with a measured moderate
lipophilicity of chrom logD 2.77 and high solubility (>10 mg/ml)
reflecting the presence of ionizable functionality. Pharmacoki-
netic (PK) studies show GSK3008348 has moderate permeability,
a favorable distribution to the site of action, high clearance and
low oral bioavailability, all appropriate for inhaled dosing (Fig. 1c)
(see supplementary methods section for PK methods).
αvβ6 affinity and RGD integrin selectivity of GSK3008348. In
recombinant soluble protein preparations, GSK3008348 exhibits a
high affinity and a minimum of 26-fold selectivity for the αvβ6
integrin over the other RGD integrin family members (Fig. 2a and
b). For the TGFβ-activating RGD integrins (αvβ1, αvβ3, αvβ5,
and αvβ8), a minimum selectivity of 182-fold (αvβ8) and max-
imum selectivity of 3375-fold (αvβ3) was demonstrated (Fig. 2b).
Of particular note, the inhibition constant for binding to the αvβ6
integrin was 190-fold higher than for the αvβ1 integrin and over a
1000-fold higher than for the αvβ3 or αvβ5 integrins (Fig. 2b).
Plasma membranes prepared from normal and IPF human lung
tissues were used to investigate the affinity of [3H]GSK3008348
for αvβ6 integrins in a disease relevant system as well as to
quantify differences in the αvβ6 integrin expression between
normal and diseased lung. [3H]GSK3008348 demonstrated a high
affinity for the αvβ6 in normal (pKD 11.0 ± 0.06 (KD 9.5 pM)) and
IPF (pKD 11.1 ± 0.07 (KD 4.8 pM)) human lung tissue membrane
preparations (Fig. 2c). A significant increase in the amount of
αvβ6 integrin was observed in IPF membranes (0.51 ± 0.11 pmol/
mg) compared with normal membranes (0.18 ± 0.02 pmol/mg)
(Fig. 2d).
GSK3008348-induced αvβ6 internalization and degradation.
The surface (membrane) and total (membrane and intracellular
pools) expression of αvβ6 integrins in normal human bronchial
epithelial (NHBE) cells were measured using flow cytometric and
imaging assays. GSK3008348 caused a significant reduction in
surface expression of αvβ6 (Fig. 3a). When cells were permeabi-
lized with saponin to allow antibodies intracellular access, there
was no significant difference observed between anti-hβ6 antibody
labeling with and without GSK3008348 (Fig. 3a). The inter-
nalization observed in the presence of GSK3008348 was inhibited
when NHBE cells were pre-incubated with the clathrin-coated pit
inhibitor chlorpromazine, whereas the lipid raft inhibitor filipin
had no effect showing endocytosis was mediated via clathrin-
coated pits (Fig. 3b). To determine the rates of ligand-induced
internalization the surface expression of αvβ6 integrin was mea-
sured over time following the addition of a maximal concentra-
tion of GSK3008348. GSK3008348 caused a rapid internalization
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Fig. 2 High affinity and selectivity of GSK3008348 for the αvβ6 integrin. a Competition binding curves of GSK3008348 against the RGD integrins
(mean ± SEM; n= 4). b pKI affinity or pIC50 values (αIIbβ3 only) for GSK3008348 against the RGD integrins with fold-selectivity for αvβ6 (mean ± SEM;
n= 4–6). c Representative saturation binding curves for [3H]GSK3008348 in normal and IPF human lung tissue (duplicate points shown ±min/max).
d Quantification of total levels of αvβ6 levels in normal and IPF human lung tissue (Box and whisker plot shows median, first and third quartiles, and max/
min values; six donors per group). Source data are provided as a Source Data file.
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of αvβ6 integrins with a t1/2 of 2.6 ± 0.5 min (Fig. 3c). Following
washout of GSK3008348 after 1 h exposure, αvβ6 integrin
returned to the surface of NHBE cells in a time-dependent
manner with a t1/2 of 11.0 ± 1.9 h (Fig. 3c).
The internalization of cell surface αvβ6 integrin was confirmed
using confocal microscopy by immunofluorescence staining of
the β6 subunit (Fig. 3d). Blocking internalization at 4 °C revealed
abundant cell surface αvβ6 integrin expression (Fig. 3d panels a
and b) and intracellular staining in cells permeabilized prior to
staining with anti-hβ6 antibody (Fig. 3d panels c and d). Staining
patterns were similar irrespective of the presence of GSK3008348.
In contrast, although vehicle controls treated cells incubated at 37
°C retained cell surface expression of αvβ6 integrin (Fig. 3d panel
e), those incubated with GSK3008348 for 1 h expressed no αvβ6
integrin on the cell surface (Fig. 3d, f) and all the intracellular
integrin showed juxtanuclear localization (Fig. 3d panel h). To
quantify the loss of αvβ6 integrin membrane staining induced by
GSK3008348 in confocal microscopy studies, the mean staining
intensity in chamber slide wells for anti-hβ6 antibody in the four
optical sections captured were calculated (Fig. 3e). In flow
cytometric assays, GSK3008348 caused concentration-dependent
ligand-induced αvβ6 integrin internalization following 2 h
incubation with NHBE cells with an pEC50 value of 9.76 ± 0.25
(EC50 0.26 nM) (Fig. 3f). No αvβ6 integrin internalization was
observed with the TGFβR1 inhibitor SB-525334 (Fig. 3f). Further
imaging studies using high-content screening were completed to
measure total αvβ6 integrin levels in the absence and presence of
the lysosomal degradation inhibitor chloroquine. Following a 24 h
incubation with GSK3008348, the levels of staining for αvβ6
integrin was significantly reduced compared with control (Fig. 3g,
h). The effect of GSK3008348 was reduced in the presence 10 µM
chloroquine, demonstrating that GSK3008348-induced lysosomal
degradation of αvβ6 post internalization. A trend toward
increased levels of αvβ6 integrin in vehicle control treated cells
exposed to the lysosomal inhibitor was also observed suggesting
inhibition of endogenous turnover of the integrin in this system
(Fig. 3g, h).
To understand whether αvβ6 integrin internalization may be
disrupted in pulmonary fibrosis, limiting efficacy GSK3008348,
internalization studies were performed in small airway epithelial
cells (SAECs) from patients with IPF (Fig. 3i) or non-diseased
controls (Fig. 3j). In both diseased and non-diseased SAECs there
was loss of cell surface αvβ6 integrin 1 h following ligation with
GSK3008348 to ~40–50% baseline levels. Whilst there was little
difference in αvβ6 integrin internalization between diseased and
non-diseased SAECs, there was a trend toward reduced total αvβ6
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Fig. 3 GSK3008348-induced internalization and degradation of the αvβ6 integrin. Flow cytometry using NHBE cells showing a ligand-induced αvβ6
internalization triggered by GSK3008348, b the effect of chlorpromazine and filipin on ligand-induced αvβ6 internalization (mean ± SEM; n= 4–6; ANOVA
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nucleus (blue)) imaged by confocal microscopy to produce a 3D cell z-stack. Representative single cells (×50 magnification; scale bar= 50 µm) from four
optical sections captured per condition with e the mean β6 marker intensity for optical sections shown (mean ± SEM from single experiment). f Flow
cytometric analysis of the concentration-dependency of GSK3008348-induced αvβ6 internalization (mean ± SEM; n= 4). g The effect of the lysosomal
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integrin in IPF derived SAECs that may reflect the different
metabolic profile seen in these cells.
NanoSPECT-CT imaging of GSK3008348 engagement with
αvβ6. We have previously shown upregulation of the αvβ6
integrin in bleomycin-induced pulmonary fibrosis using a non-
invasive imaging (single photon electron computed tomography
(SPECT)) of a highly selective radioligand for the αvβ6 integrin
([111In]-DTPA-A20FMDV2)22. Therefore, this system was used
to measure the engagement of GSK3008348 with αvβ6 integrins
in the lung in vivo. GSK3008348 caused complete inhibition of
αvβ6 integrin specific radioligand binding in both saline control
and bleomycin-treated mice 2 h following dosing (Fig. 4a, b). This
confirmed that GSK3008348 could completely inhibit radioligand
binding via inhaled delivery, even when αvβ6 integrins have been
upregulated in fibrotic mouse lung. Dose-dependent inhibition of
radioligand binding 2 h post-intranasal (i.n.) dosing was also
observed with 0.05 µg/kg and 50 µg/kg of GSK3008348 (Fig. 4c).
In an additional study in naive mice a significant inhibition of
radioligand binding was also observed 8 h post-i.n. dosing of 1
mg/kg GSK3008348 (Supplementary Fig. 1). In PK studies com-
pleted in C57BL/6 mice dosed with 1 mg/kg i.n. GSK3008348,
lung levels of drug were shown to be below the lower limit of
quantitation (2 ng/lung (~4 nM)) from 4 h post dosing (Supple-
mentary Table 1).
Inhibition of αvβ6-mediated TGFβ activation by GSK3008348.
To demonstrate the functional activity of GSK3008348, NHBE
cells were used to measure TGFβ activation. GSK3008348
inhibited Smad2 phosphorylation in a concentration-dependent
manner, as did the TGFβR1 inhibitor SB-525334 and the αvβ6
integrin selective peptide A20FMDV2 (Fig. 5a). The maximal
level of inhibition achieved for GSK3008348, SB-525334, and
A20FMDV2 were comparable showing that TGFβ activation in
this system was mediated via αvβ6 integrins. The pIC50 (IC50)
values for inhibition of αvβ6-mediated TGFβ activation were 9.13
± 0.04 (0.15 nM), 8.25 ± 0.14 (3.5 nM), and 7.28 ± 0.13 (26.8 nM)
for GSK3008348, A20FMDV2, and SB-525334, respectively. To
further investigate the mechanism by which GSK3008348 caused
a prolonged inhibition of αvβ6-mediated TGFβ release from
NHBE cells, washout studies were completed in the presence and
absence of the lysosomal degradation inhibitor chloroquine.
GSK3008348 caused inhibition of TGFβ activation in the pre-
sence and absence of chloroquine (Fig. 5b). In the absence of
chloroquine, the inhibitory effect observed for GSK3008348 was
only partially reversed following washout. The partial reversal of
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Fig. 4 In vivo engagement of αvβ6 via the inhaled route in a fibrotic lung. a Effect of GSK3008348 on the binding of the selective αvβ6 integrin
nanoSPECT-CT ligand [111In]A20FMDV2 in naive (saline treated) and bleomycin-treated mice following i.n. dosing (mean ± SEM; n= 5–6 animals per
group; ANOVA with Fisher’s LSD post test comparisons versus corresponding vehicle or IgG2A control or between active groups). b Representative axial
SPECT/CT scans of thorax detected binding of [111In]A20FMDV2 in lungs of naive (saline treated) or bleomycin-treated mice receiving vehicle (i.n. saline)
or GSK3008348 (1 mg/kg) from the study shown in panel a. c Dose-dependent effect of GSK3008348 on the binding of the selective αvβ6 integrin
nanoSPECT-CT ligand [111In]A20FMDV2 in bleomycin-treated mice following i.n. dosing (mean ± SEM; n= 6–12 animals per group; ANOVA with Fisher’s
LSD post test comparisons versus vehicle i.n. control). Representative axial SPECT/CT scans of thorax detected binding of [111In]A20FMDV2 also shown.
Source data are provided as a Source Data file.
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Fig. 5 Inhibition of αvβ6-mediated TGFβ activation in vitro and in vivo by GSK3008348. a Concentration-dependent inhibition of pSmad2 levels in
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(expressing the firefly luciferase under the control of a TGFβ-sensitive portion of the PAI-1 promoter) co-culture system (mean ± SEM; n= 4–8; Student’s
t test). Effect of GSK3008348 (i.n.) versus SB-525334 (p.o.) on the levels of pSmad2 in c lung tissue and d BAL cells from bleomycin-treated mice (mean ±
SEM; n= 5–10 animals per group; ANOVA with Fisher’s LSD post test comparisons). e Concentration-dependent effect of GSK3008348 on pSmad2 levels
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GSK3008348 inhibition caused by washout in the absence of
chloroquine was significantly reduced in the presence of chlor-
oquine (Fig. 5b).
To measure the functional inhibition of αvβ6-mediated TGFβ
over time in vivo, pSmad2 levels were measured in both lung
tissue and cells present in bronchoalveolar lavage (BAL) following
administration of GSK3008348. Mice challenged with 1 mg/kg
(20IU) bleomycin showed an increase in the pSmad2 levels in the
lungs after 14 days relative to saline controls. (Fig. 5c). Following
a single therapeutic i.n. dose of GSK3008348 (1 mg/kg) in
bleomycin-challenged animals, a significant reduction in pSmad2
was observed in lung tissue when compared with saline treated
animals at 4 and 8 h post dosing (Fig. 5c) despite levels of drug
being unmeasurable in the lung 2 h post dosing (Supplementary
Table 1). By 24 h the pSmad2 in the bleomycin/GSK3008348-
treated animals had returned to levels comparable with those
observed in the lung tissue from bleomycin/vehicle-treated
animals (Fig. 5c). The percentage inhibitions at 4, 8, and 24 h
were calculated to be 75%, 62%, and 9%, respectively. These
findings were also observed in the BAL cells of these same
animals, where GSK3008348 caused a reduction in pSmad2 in
BAL cells from bleomycin-treated animals compared with BAL
cells from bleomycin/vehicle-treated control animals. By 24 h, the
levels of pSmad2 in the BAL cells from bleomycin/GSK3008348-
treated animals had returned to levels comparable with those
observed in BAL cells from bleomycin/vehicle-treated animals
(Fig. 5d). The TGFβR1 inhibitor, SB-525334 was shown to
significantly reduce pSmad2 levels in both lung tissue and BAL
cells 2 h post dosing (Fig. 5c, d). Levels of lung tissue pSmad2 in
the bleomycin/TGFβR1 inhibitor group were significantly lower
than in the saline/vehicle group, suggesting that under normal
conditions there is a basal level of TGFβ activity in the lungs.
However, GSK3008348, which reduces active TGFβ levels
through αvβ6 inhibition, did not inhibit pSmad2 below this
basal activity at the dose tested. The pattern of dose-dependent
inhibition of pSmad2 in bleomycin-challenged animals with
GSK3008348 was comparable to that observed in CT/SPECT
studies (Fig. 4 and Supplementary Fig. 2).
To provide a link between pre-clinical and clinical studies, the
effect of GSK3008348 was measured in precision cut lung slices
(PCLS) from IPF patients. GSK3008348 caused a concentration-
dependent reduction in pSmad2 phosphorylation (Fig. 5e) with
an approximate IC50 of 3 nM. Levels of lung tissue pSmad2
following inhibition of TGFβR1 with SB-525334 in murine and
human fibrosis was lower than inhibition by GSK3008348,
suggesting that under normal conditions there is a basal level of
TGFβ activity in the lungs which was not inhibited by
GSK3008348 at the concentrations tested. It is possible that
some of the residual TGFβ activity in the lung is due to activation
by the αvβ1 integrin, therefore the αvβ1 inhibitor c8, and the
αvβ3/αvβ5 inhibitor SB-267268, were assessed. Neither com-
pound inhibited pSmad2 levels (Fig. 6f). These data suggest that
in this system, the αvβ6 integrin is both necessary and sufficient
for activating TGFβ in fibrotic lung.
GSK3008348 effects on PD and disease biomarkers. To further
clarify the drug effects on PD and disease biomarkers, a number
of analytes that are known to reflect fibrogenic end points,
including analytes previously identified in the PROFILE (Pro-
spective Observation of Fibrosis in the Lung Clinical End points)
study23 were investigated in a murine pulmonary fibrosis model.
Animals were exposed to 3 mg/kg (60IU) bleomycin for 14 days
following subcutaneous (s.c.) implantation of osmotic pumps
containing GSK3008348 or vehicle 3 days before. Bleomycin
treatment increased both total lung collagen as measured by
hydroxyproline levels (Fig. 6b) and serum levels of the matrix
metalloprotease (MMP)-degraded ECM protein neoepitope C3M
(Fig. 6c), which is known to reflect progressive IPF in patients.
There was partial inhibition of hydroxyproline levels in the lungs
of bleomycin-treated mice following prophylactic administration
of GSK3008348 (Fig. 6b) but a substantial inhibition of serum
C3M was detected in response to GSK3008348 (Fig. 6c).
TGFβ activation was also assessed in the lungs of IPF patients
following collection of bronchoalveolar lavage fluid (BALF).
Samples were obtained from healthy volunteers and IPF patients
and the level of pSmad2 in BAL cells was measured along with
TGFβ-induced gene h3 (βIG-H3) and plasminogen activator
inhibitor-1 (PAI-1) within the BALF. All three biomarkers were
significantly increased in IPF patients compared with healthy
volunteers (Fig. 6d, e). To determine whether these markers could
serve as PD biomarkers in a clinical study using GSK3008348 we
also measured these analytes in samples collected from the study
assessing the effects of prophylactic dosing with GSK3008348 in
the bleomycin model of pulmonary fibrosis. There was a
significant increase in lung tissue pSmad2 levels 14 days post
instillation of bleomycin and phosphorylation of Smad2 was
inhibited by GSK3008348 (Fig. 6f). Furthermore, GSK3008348
also inhibited bleomycin-induced increases in the level of βIG-H3
and PAI-1 detected in BALF (Fig. 6g). Finally, to determine
whether local delivery of inhaled αvβ6 inhibitor could be used to
ameliorate established fibrotic lung disease, therapeutic dosing of
i.n. GSK3008348 was undertaken. Bleomycin-induced pulmonary
fibrosis was induced with a 3 mg/kg oropharyngeal dose and after
14 days, at the time of established fibrosis, GSK3008348 was
instilled twice daily i.n. for a further 14 days and fibrosis was
assessed (Fig. 7a). Animals receiving vehicle control showed an
increase in hydroxyproline (Fig. 7b) and areas of focal fibrosis
assessed by histology (Fig. 7c) where those receiving twice daily i.
n. αvβ6 inhibitor showed a significant reduction in fibrosis as
measured by both hydroxyproline and histology (Fig. 7b, c).
Discussion
The small molecule RGD-mimetic αvβ6 inhibitor GSK3008348
represents a therapeutic agent for inhaled delivery to IPF patients
and is the first in class inhaled integrin inhibitor to reach clinical
development. GSK3008348 resides in a distinct niche, not only in
the current IPF therapeutic pipeline space, but also as one of the
highest affinity integrin inhibitors that has been developed in the
field of small and large molecule drug discovery14. The aim of this
study was to fully characterize GSK3008348 and generate trans-
lational drug discovery biomarkers that will facilitate the per-
formance of future clinical trials. To date, GSK3008348 has been
shown to be safe and well tolerated in phase I healthy volunteer
studies24 and has completed a phase Ib study, demonstrating
target engagement of the αvβ6 integrin in IPF patients25.
It is hypothesized that the αvβ6 integrin is a key driver of TGFβ
activation in IPF and therefore an attractive therapeutic target in
this, and other, fibrotic diseases10–13. A highly selective αvβ6
integrin inhibitor was designed for topical delivery to the lungs to
improve target engagement, reduce the dose, and minimize sys-
temic exposure and potential adverse effects. A concern with this
approach has been the risk of being unable to deliver drug to the
peripheral regions of the lung where the fibrosis occurs in IPF,
however, a recent study using 99mTechnetium-labeled salbutamol
has shown that nebulized drug can be delivered to these fibrotic
regions26. During development of GSK3008348, characterization
of the pharmacology, the physico-chemical, and PK properties of
the molecule were assessed to track suitability for inhaled deliv-
ery. Most of these properties were evident in the GSK3008348
molecule except for lung retention27. Therefore, the duration of
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action of this inhaled molecule was designed to be driven by the
PD of the interaction between GSK3008348 and the αvβ6
integrin.
GSK3008348 demonstrates a high affinity for the αvβ6 integrin
in soluble protein preparations but more importantly in plasma
membranes generated from fibrotic regions of human IPF lung.
The use of a radiolabeled version of GSK3008348 has enabled
expression levels of αvβ6 integrins to be accurately quantified in
normal and IPF lung. First, this has confirmed and quantified the
upregulation of αvβ6 integrins in IPF previously observed semi-
quantitatively using immunohistochemistry12. Second, the
amount of integrin present in disease tissue can be incorporated
into more accurate models to predict the therapeutic dose of αvβ6
integrin inhibitors. NanoSPECT-CT imaging studies using
A20FMDV2 in saline and bleomycin-treated mice demonstrated
the dose- and time-dependent engagement of GSK3008348 with
αvβ6 in an in vivo model of lung fibrosis. The quantification of
αvβ6 integrin upregulation in IPF and the profiling of
GSK3008348 binding to the integrin in diseased tissue will allow
this pre-clinical work to be translated to clinical studies in
IPF25,28.
It has been demonstrated for RGD-peptides that binding to
αvβ6 integrin induces internalization, followed by a delay in the
return of the integrin to the cell surface29,30. In this study,
GSK3008348-induced rapid internalization of the αvβ6 integrin
that was concentration-, time-, and clathrin-dependent, in
agreement with published data31. Following washout of
GSK3008348, the return of αvβ6 integrins to the cell surface was
markedly slower compared with endogenous turnover31 as well as
post internalization via RGD-peptides30. Furthermore, in NHBE
cells in the constant presence of GSK3008348 over 24 h, a com-
plete loss of αvβ6 integrins was also observed at both the cell
surface and intracellularly. Both these observations suggest that
the internalized GSK3008348–αvβ6 complex is degraded and that
returning αvβ6 integrins in washout studies are newly synthe-
sized. Furthermore, in washout experiments investigating αvβ6-
mediated inhibition of TGFβ activation, the sustained inhibition
observed with GSK3008348 was prevented in the presence of
chloroquine. These observations suggest that GSK3008348
induces internalization of αvβ6 integrins that are subsequently
sorted for degradation in lysosomes. The high affinity of
GSK3008348 for the αvβ6 integrin combined with its previously
described fast association and slow dissociation profile32 likely
results in a prolonged activation of the integrin in intracellular
vesicles. We hypothesize that the longer the integrin is engaged at
the RGD-site post internalization, the more likely it is to be
intracellularly designated for degradation. This effect has pre-
viously been observed with other small molecule/protein
interactions33,34 and would ultimately result in the prolonged
duration of inhibition of TGFβ activation in vivo demonstrated in
this study.
One of the current challenges of clinical study design within
the IPF field is the size and duration of studies required to
measure meaningful changes in lung function or mortality,
especially in addition to standard of care4–7. Therefore, there have
been significant efforts to identify IPF biomarkers detectable in
blood or BALF samples that reflect disease biology and which
could be used as early surrogates for long-term decline in forced
vital capacity or mortality, predict disease progression and allow
enrichment of patient cohorts for clinical studies as well as
facilitating potentially shorter and smaller studies.
The purpose of the bleomycin model of fibrosis in these studies
was twofold. Initial studies were designed primarily to assess
target engagement and effects on TGFβ signaling and other PD
biomarkers rather than to predict clinical efficacy. Therefore,
these studies used a low bleomycin dose (1 mg/kg) to induce a
mild bleomycin injury and minimize distress to animals where
possible. A higher dose of bleomycin (3 mg/kg) was used in
studies in which fibrotic end points (hydroxyproline) were
assessed including both the prophylactic and therapeutic dosing
studies with GSK3008348. We demonstrated that prophylactic
treatment with GSK3008348 led to a modest inhibition of lung
hydroxyproline similar to values reported following prophylactic
dosing with nintedanib in bleomycin-treated mice35. Subsequent
studies were used to assess the feasibility of inhaled small mole-
cules to penetrate and ameliorate established lung fibrosis, and
indeed 2 weeks inhaled GSK3008348 lead to a substantial
reduction in established fibrosis as measured by total lung col-
lagen and histological assessment. However, there are known
limitations of the bleomycin model of pulmonary fibrosis that
mean it cannot reliably predict the clinical effectiveness of an
anti-fibrotic therapy36. Therefore, to ensure the translational
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efficacy of GSK3008348 could be determined, we also measured
the effects of GSK3008348 on established and recently identified
biomarkers each of which could be translated rapidly into clinical
practice. Initial studies evaluated the effects of GSK3008348 on
TGFβ activation pathways. These data established that levels of
pSmad2 measured in BAL cells recovered from the fibrotic lungs
of bleomycin-treated mice were reduced following administration
of GSK3008348 in comparison with vehicle control treated mice,
thus demonstrating engagement of the mechanism in the lung.
Furthermore, proteins known to be regulated by active TGFβ
including PAI-1 and βIG-H3, were also inhibited by GSK3008348
in mouse BALF confirming the effects of GSK3008348 on the
TGFβ activation pathway and offering further options for mea-
suring a PD effect on this signaling pathway in clinical studies.
Moreover, we demonstrated that GSK3008348 could inhibit
pSmad2 in human diseased samples using PCLS from IPF
patients confirming that GSK3008348 can inhibit TGFβ activa-
tion pathways both in human fibrotic tissue as well as a murine
model of lung fibrosis. These data suggest that measuring levels of
pSmad2 in BAL cells obtained from clinical studies in the pre-
sence of GSK3008348 could be a good surrogate measure of the
effects of this αvβ6 inhibitor on TGFβ activation in IPF lung. One
promising and recently identified serum biomarker in IPF is the
MMP-degraded ECM protein neoepitope C3M, which is also
raised in the bleomycin model of lung fibrosis37 and is associated
with disease progression and mortality in patients with IPF23. We
demonstrated that GSK3008348 was able to inhibit serum C3M in
the murine model of bleomycin-induced fibrosis and may
therefore be useful as a mechanism-specific biomarker in future
IPF clinical trials.
Although αvβ6 integrins are considered to drive the majority of
TGFβ activation in IPF, there are data suggesting a role for αvβ538
and, more recently, αvβ119. However, data generated in this study
utilizing PCLS from diseased human IPF tissue has compared the
effects of GSK3008348 with highly selective αvβ1 (c8) and αvβ5
inhibitors and shown that of these the αvβ6 integrin appears to be
the major contributor to TGFβ activation and downstream
phosphorylation of Smad2 in this system. The comparable
potency for inhibition of pSmad2 in primary cells and in human
lung tissue suggests that the epithelial αvβ6 integrin is the main
driver of TGFβ activation in human IPF tissue. However, this
does not discount a potential role of other integrins in the
pathogenesis of pulmonary fibrosis. Although epithelial cell injury
may be a driver of pulmonary fibrosis, myofibroblasts are a key
effector cell and fibroblast to myofibroblast differentiation is a
major step in this process. Active TGFβ is well known to induce
myofibroblast differentiation, which is mediated in part through
Smad signaling, but also by non-canonical activation of focal
adhesion kinase (FAK) through interactions with integrins39.
Therefore, even if epithelial cells do generate sufficient active
TGFβ to lead to downstream TGFβ signaling in neighboring
fibroblasts, as these data suggest, it is possible that myofibroblasts
develop autonomous, non-canonical, pro-fibrotic pathways
through TGFβ induced αvβ1 integrin and FAK activation that
will not be inhibited by GSK3008348. Therefore, further studies
are required to determine the relative contribution of αvβ1 and
αvβ6 integrins on myofibroblast differentiation.
This study has some strengths and limitations that will only be
fully addressed in clinical studies with GSK3008348. A key
strength of this study is the demonstration that twice daily (b.i.d.)
inhaled dosing can ameliorate established bleomycin-induced
pulmonary fibrosis. This is especially important in light of the
recent early termination of the STX100 study owing to safety
concerns. Although it is not known at the current time whether
the adverse effects of STX100 were due to on- target effects, the
difference in drug delivery (i.n. versus s.c.), dosing schedule (b.i.d.
versus weekly) and TGFβ inhibition (reduced rather than blocked
completely) offer considerable advantages for GSK3008348
compared with the αvβ6 antibody blocking approach. The addi-
tional strengths of this study are the comprehensive assessment of
both the anti-fibrotic potential and target engagement of the
molecule using both human and murine model systems in
addition to measuring both traditional biochemical and clinically
translatable end points. Limitations include use of the bleomycin
mouse model of lung fibrosis that is recognized to be a poor
surrogate for clinical efficacy in IPF. However, the use of the
bleomycin model in this study has been to demonstrate that
inhaled delivery of an integrin inhibitor can mitigate established
fibrosis and to establish PD and mechanism-specific biomarkers.
These data demonstrate that inhalation of a small molecule can
penetrate fibrotic lung and the biomarkers studies demonstrate
proof of mechanism that can be further assessed in future IPF
clinical trials. Thus, these data have been used to create a clear
clinical translational pathway and to generate and test a
hypothesis, rather than to raise unrealistic hopes for clinical
efficacy at this stage of pre-clinical development.
All the data generated as part of this study have contributed to
the design and clinical dose prediction used for GSK3008348 in
phase Ib studies where the ability of this molecule to engage the
αvβ6 integrin in IPF patients is currently under investigation25.
Based on this translational data package the hypothesized
mechanism of action of GSK3008348 post administration into an
IPF patient’s lung is as follows: (1) nebulized GSK3008348 would
enter the lung and bind to αvβ6 with high affinity and fast
association kinetics. (2) The GSK3008348/αvβ6 complex would
then be rapidly internalized in minutes and the integrin degraded
in lysosomes. (3) The αvβ6-mediated TGFβ activation in the IPF
lung would be inhibited reducing pro-fibrotic mediators and
extracellular matrix deposition. These studies therefore represent
a different approach to pre-clinical drug development that will
reduce the chances of failed translation to early phase clinical
studies and increase the prospect of generating effective therapies
for IPF.
Methods
Study design. The objective of this study was to develop a clear path for a pro-
posed IPF therapeutic from pre-clinical to clinical studies that linked target
engagement through to functional inhibition of PD and disease end points. In
order to achieve this, studies focused on human primary cells and IPF disease tissue
in in vitro and ex vivo studies to characterize the pharmacology of an αvβ6 RGD-
mimetic inhibitor investigating binding, receptor internalization and inhibition of
TGFβ. Studies investigating these end points in vivo were then completed using a
mouse model of pulmonary fibrosis, with disease end point relevance and vali-
dation determined in ex vivo BAL cell and fluid from IPF patients that could be
readily profiled in future clinical experiments.
All animal studies were approved by the University of Nottingham Animal
Welfare and Ethical Review Board and carried out in accordance with Animals
(Scientific Procedures) Act 1986, the GSK Policy on the Care, Welfare and
Treatment of Animals and the ARRIVE (Animal Research: Reporting of In Vivo
Experiments) guidelines40. Mice were randomized into treatment groups and for
initial studies sample size was selected based on experience of the model. In
subsequent studies, power analysis was completed on the previous studies data to
determine sample size.
The human biological samples were sourced ethically, and their use in research
use complied with the terms of the written informed consents and under an IRB/
EC approved ethics protocol at each institution. Normal (healthy non-fibrotic)
human lungs (designated by medical history) from organ donors were obtained
from the National Disease Research Interchange (Philadelphia, PA, USA) in
accordance with local human biological sample management procedures. Lung
tissue samples from patients with IPF undergoing lung transplantation were
obtained from the Institute of Transplantation at Newcastle Upon Tyne Hospitals.
All patients had their IPF diagnosis confirmed based on their medical history and
evaluation of their explanted lung tissue by a board-certified respiratory
pathologist. Tissue was obtained in accordance with local human biological sample
management procedures which was approved by regional ethics approval (11/NE/
0291). BAL samples were obtained from IPF patient at the National Institute for
Health Research Respiratory Biomedical Research Unit (Royal Brompton Hospital,
London, UK) as part of routine diagnostic BAL in the PROFILE study23.
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All chemicals and reagents were purchased from Sigma-Aldrich Co. Ltd.
(Gillingham, Kent, UK) and antibodies from R&D Systems (Minneapolis,
MN, USA) unless otherwise stated. All tissue culture flasks and plates were
purchased from Greiner Bio-One (Firckenhausen, Germany). All in vitro studies
were completed at least three times and at 37 °C, unless otherwise stated. Cellular
assays were completed in an atmosphere of 5% CO2 with a relative humidity of
95% at 37 °C.
Synthesis of inhibitors. The small molecule compounds GSK300834821, c8 (αvβ1
inhibitor19), SB-525334 (TGFβR1 inhibitor41), and SB-267268 (αvβ3/αvβ5 inhi-
bitor42) used in this study were synthesized by the Fibrosis DPU Medicinal
Chemistry group at GlaxoSmithKline Medicines Research Centre (Stevenage,
Hertfordshire, UK). The αvβ6 selective peptide A20FMDV243 was synthesized by
Cambridge Research Biochemicals (Cleveland, UK).
Radioligand binding assays. Radioligand binding and platelet aggregation (αIIbβ3
only) assays were completed against the RGD integrins. All radioligand binding
experiments were performed in 96-deep well plates at 37 °C in binding buffer (25
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 100 mM NaCl, 2 mM
MgCl2 and 1 mM 3-[(3-cholamidopropyl)dime thylammonio]-1-propanesulfonate
at pH 7.4 (NaOH)) in a total volume of either 0.5 ml or 1.5 ml (1.5 ml for
saturation binding studies with lung parenchyma membranes) consisting of 50 µl/
well of either unlabeled compound at varying concentrations or vehicle (1%
dimethyl sulphoxide; DMSO), 50 µl of [3H]RGD ligand32 or [3H]GSK3008348 and
either 0.4 or 1.4 ml/well of purified integrin or membranes (concentration
dependent on the number of binding sites of individual soluble protein or mem-
brane fragment preparations). Non-specific binding (NSB) was determined with
10 µM SC-68448 (pan-αv RGD small molecule32) except for saturation binding
experiments with lung membranes where 10 µM A20FMDV2 (selective αvβ6 RGD-
peptide) was used. Specific binding was measured by subtracting the NSB from the
total radioligand binding in the presence of vehicle (1% DMSO). Binding was
terminated by rapid vacuum filtration and the amount of specific radioligand
bound was measured by LS spectroscopy using a TriCarb 2900 TR LS counter
(PerkinElmer LAS UK Ltd., Beaconsfield, UK). Binding assays were completed in
the presence of 2 mM Mg2+ to standardize integrin activation state.
For platelet aggregation, platelets were resuspended in assay buffer (5 mM
HEPES, 140 mM NaCl, 3 mM KCl, 12 mM NaHCO3, 7 mM KH2PO4, and 60 mM
D-glucose at pH 7.4 (NaOH)), and resuspended to 4 × 108 cells/ml. Cells were then
incubated for 30 min at ambient temperature (20–22 °C) with the addition of 0.75
mM MgCl2, 1.5 mM CaCl2, and 0.4 mg/ml fibrinogen and added to clear 96-well
flat bottomed plate (90 µl/well) containing 10 µl/well vehicle (0.1% DMSO in
platelet aggregation assay buffer) or test compounds. Plates were then sealed and
incubated for 20 min at 37 °C prior to a basal absorbance read where the optical
density of each well was read on a SpectraMax Plus 384 (Molecular Devices,
Sunnyvale, CA, USA) set to 450 nm. Following the addition of 10 µl/well adenosine
diphosphate the optical density of each well was read at 450 nm every 20 s over a 6
min kinetic time course read with the basal absorbance read used to measure the %
inhibition of platelet aggregation over the kinetic time course read.
Cell culture. NHBE were purchased from Lonza (Lonza Group Ltd, Basel, Swit-
zerland) and placed into culture as a monolayer adhered in type I collagen coated
tissue culture flasks using aseptic techniques. Cells were maintained in NHBE cell
medium (bronchial epithelial growth medium (BEGM) containing 0.6 mM/l MgCl)
supplemented with BEGM CloneticsTM SingleQuots (containing bovine pituitary
extract, insulin, hydrocortisone, GA-1000 (consisting of 30 mg/ml gentamicin and
15 μg/ml amphotericin), retinoic acid, transferrin, triiodothyronine, epinephrine,
and human epidermal growth factor)) in 95%:5% air:CO2 and were harvested when
~80% confluent using Accutase®. Cells were then resuspended in phosphate-
buffered saline (PBS), centrifuged at 300 × g for 5 min prior to re-suspension in
either NHBE cell medium or flow cytometry buffer (RPMI 1640 (without L-glu-
tamine and phenol red) containing 10 mM/l HEPES, 1% w/v bovine serum albu-
min (BSA) and 2 mM/l MgCl2.
Cultures of SAEC from explanted IPF lung tissue were established from
brushings collected from airways of <2 mm in diameter. Cells were cultured in
Small Airway Growth Media (Promocell) and used at P4 or less in experiments.
SAEC exhibit the typical cobblestone appearance of an epithelial cell monolayer in
culture, express epithelial markers (Cytokeratin-17 and E-cadherin) but are
negative for mesenchymal (fibronectin), leukocyte (CD45), alveolar macrophage
(CD68), and endothelial (CD31/PECAM) markers. Cells were lifted from flasks
with Trysin ethylenediaminetetraacetic acid (EDTA) solution, washed in complete
media, centrifuged at 300 × g for 5 min prior and resuspended in flow cytometry
buffer for analysis.
The epithelial transformed mink lung cell (TMLC) line that expresses firefly
luciferase under the control of a TGFβ-sensitive portion of the PAI-1 promoter44
was obtained from Professor Daniel Rifkin (New York University, NY, USA) and
maintained in culture in DMEM containing 10% fetal bovine serum with 2 mM
L-glutamine, penicillin/streptomycin, and 200 μg/ml G418. Cells were lifted from
flasks with 5 mM EDTA, washed in PBS with 0.5% BSA, counted by
hemocytometer, and plated in 96-well plates.
Flow cytometry and imaging assays. The measurement of surface and intra-
cellular αvβ6 in NHBE cells and SAEC cells was determined via flow cytometry.
NHBE flow cytometry assays were performed in 96-well polypropylene microplates
with NHBE cells suspended in flow cytometry buffer (45 μl/well with 70,000 cells/
well) in the presence of appropriate concentrations of drug or vehicle (0.1%
DMSO) as required. Where stated, cells were permeabilised by incubating with
0.2% w/v saponin for 5 min at ambient temperature (20–22 °C) prior to com-
pound/vehicle addition. Inhibition of clathrin or lipid raft mediated endocytosis
was investigated by pre-incubating NHBE cells with either 2 μg/ml chlorpromazine
or 10 μg/ml filipin, respectively, for 5 min prior to addition of compound or vehicle
(0.1% DMSO). SAEC flow cytometry assays were performed in flow cytometry
tubes with 100,000 cells in a 100 μl volume of flow cytometry buffer in the presence
of GSK3008348 or vehicle (0.1% DMSO). All experiments were stopped by addi-
tion of 10 μl per well/tube of IgG2B-PE or hβ6-PE and incubation at 4 °C for 1 h.
Cells were then washed twice by centrifuging at 300 × g for 5 min, removing
supernatant and adding flow cytometry buffer (150 μl/well). After the second wash
cells were resuspended in flow cytometry buffer (200 μl/well) and cell suspensions
transferred into a 96-well round bottom polypropylene plate (Corning Inc. Life
Sciences, Tewksbury, MA, USA) or flow cytometry tubes. Cell samples were then
acquired on a fluorescence-activated cell sorting (FACS) Canto II (BD Biosciences,
San Jose, CA, USA) using a high throughput sampler system and BD FACS
DivaTM version 6.1.3 software. Cells were identified by their forward and side-
scatter characteristics and a single population gated with cell debris excluded
(Supplementary Fig. 3) and the mean fluorescence intensity (MFI) of antibody
conjugated cells measured. The fluorescence was quantified on at least 5000 cells
and following acquisition all data was exported as flow cytometry standard format
3.0 files with raw data values captured as MFI. Fluorescence-activated cell analyses
histograms were plotted using FlowJo software (Tree Star Inc. Ashland, OR, USA).
For internalization, concentration–response curves NHBE cells were added to
96-well polypropylene microplates containing 5 μl/well compound at varying
concentrations or vehicle 0.1% DMSO). Plates were incubated for 2 h in 95%:5%
air:CO2 at 37 °C prior to addition of 10 μl IgG2B-PE or hβ6-PE antibody. For
determining the rate of ligand-induced αvβ6 internalization NHBE cells were
added to 96-well polypropylene microplates containing 5 μl/well compound (at a
concentration that caused maximal internalization) or vehicle (0.1% DMSO). Plates
were incubated in 95%:5% air:CO2 at 37 °C for varying times up to 1 h and then
transferred immediately on to ice to stop any further internalization. In all, 10 μl/
well IgG2B-PE or hβ6-PE antibody were then added to plates. For determining the
rate of αvβ6 return to the cell surface (reversal of ligand-induced αvβ6
internalization), NHBE cells were added to 96-well polypropylene microplates
containing 5 μl/well compound (at a concentration that caused maximal
internalization) or vehicle (0.1% DMSO). Plates were incubated in 95%:5% air:CO2
at 37 °C for 1 h then centrifuged at 500 × g for 5 min, supernatant removed and cell
pellets resuspended in PBS (150 μl/well). This process was repeated prior to re-
suspension of cells in cell medium (150 μl/well) and incubation for varying times
up to 48 h. Plates were then transferred on to ice and 10 μl/well IgG2B-PE or hβ6-
PE antibody added. All samples were then processed and read on the FACS Canto
II as detailed above.
For cell imaging studies, NHBE cells were adhered in glass chamber slides and
incubated with vehicle (0.1% DMSO) or GSK3008348 in the absence or presence of
10 µM chloroquine for 2 h prior to β6 integrin staining with sheep anti-human
integrin β6 antibody then donkey anti-sheep IgG Alexa Fluor® 488 antibody
(Invitrogen Ltd., Renfrewshire, UK). Chamber slides were imaged with a Leica TCS
SP5 confocal microscope (Leica Microsystems Inc., Buckinghamshire, UK) to
produce a 3D cell z-stack. Quantitative analysis of the intensity of β6 staining was
completed using Columbus™ Image Data Storage and Analysis System
(PerkinElmer LAS UK Ltd., Buckinghamshire, UK). For high-content screening
(HCS) studies, supplement starved NHBE cells were plated in collagen I coated 96-
well imaging plates and treated with vehicle (0.1% DMSO) or GSK3008348 in the
presence or absence of 10 μM chloroquine for 24 h prior to β6 integrin staining
with mouse anti-human integrin β6 then goat anti-mouse IgG Alexa Fluor® 488
antibody (Invitrogen Ltd., Renfrewshire, UK). Image acquisition and analysis of
stained cells were performed using the Arrayscan VTI High Content Reader
(Thermo Fisher Scientific, MA, USA), applying bioapplications to quantify total β6
immunofluorescence. For all imaging studies, nuclear staining was completed with
Hoechst 33342 dye (Invitrogen Ltd., Renfrewshire, UK) and if required cells were
permeabilised with 0.2% w/v saponin (flow cytometry) or Triton X-100 (HCS) to
determine total αvβ6 staining (membrane and intracellular).
TGFβ activation and signaling assays. To determine activation of TGFβ via αvβ6
in NHBE cells following washout, a TMLC co-culture system was used. Cultured
NHBE cells were harvested, resuspended in NHBE cell medium and 25,000 cells
(100 µl/well) seeded in 96-well clear collagen I coated plates then left for 24 h to
adhere in 95%:5% air:CO2 at 37 °C before removal of medium. Cultured TMLCs
were harvested, resuspended in TMLC co-culture medium containing 20 µM
lysophosphatidic acid (LPA) and 25,000 cells (100 µl/well) seeded onto the NHBE
cells. Vehicle (0.1% DMSO) or test compounds were then added (10 μl/well) and
plates incubated for 24 h in 95%:5% air:CO2 at 37 °C. Supernatants were then
removed from the NHBE cell/TMLC co-culture and 100 μl/well PBS (containing 1
mM CaCl2 and 1 mM MgCl2) and 100 μl/well Steady-Glo® Reagent (Promega
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Corporation, Madison, WI, USA) added. Plates were then incubated at ambient
temperature (20–22 °C) for 5 min before supernatants were transferred to 96-well
white, solid bottom plates and luminescence read on a MicroBeta® TriLux (Per-
kinElmer LAS UK Ltd., Beaconsfield, UK). For washout studies, vehicle (0.1%
DMSO) or GSK3008348 in the absence or presence of 10 µM chloroquine were
incubated with the NHBE cell/TMLC co-culture for 1 h prior to washout. Washout
studies were also completed in the presence of chloroquine (10 µM made up in
TMLC co-culture medium). TGFβ was quantified by comparing values obtained
under experimental conditions to readings obtained from a standard curve derived
from increasing concentrations of active TGFβ added to the co-culture under
identical conditions.
TGFβ levels in supernatants harvested from human IPF PCLSs were determined
by incubation with TMLC cells for 18 h. For the measurement of concentration-
dependent effects of αvβ6 and TGFβR1 inhibitors on TGFβ activation and
signaling in NHBE cells, pSmad2 (normalized to GAPDH) was measured. pSmad2
and GAPDH was quantified using the Milliplex TGFβ Signaling Magnetic Bead
Panel 6 plex (Merck Millipore, Billerica, MA, USA) luminex assay according to the
manufacturer’s instructions. pSmad2 was determined using the same method for
in vivo and ex vivo tissue and BAL samples, however data were normalized to
tSmad2. tSmad2 was measured in the Pathscan Total Smad2 sandwich ELISA kit
(Cell Signaling Technologies, London, UK), according to the manufacturer’s
instructions with standard curves generated using recombinant GST-Smad2. βIG-
H3 was determined in mouse and human BAL fluid samples using the mouse or
human βIG-H3 DuoSet ELISA kit (R&D Systems, Abingdon, USA) respectively,
according to the manufacturer’s instructions. PAI-1 was determined in mouse and
human BAL fluid samples using the mouse or human PAI-1 Total antigen ELISA
kit (Molecular Innovations, Novi, MI, USA) respectively, according to the
manufacturer’s instructions.
In vivo mouse studies. Male C57BL/6 mice (6–12 weeks old from Charles River,
Kent, UK) were acclimatized for 5–7 days before undergoing procedures and
ranged from 16 to 28 g at the time of study. Animal welfare followed the
requirements of the Home Office Code of Practice for the Housing and Care of
Animals used in Scientific Procedures. In brief, mice were housed in individually
ventilated cages in groups of three to four in a temperature and humidity con-
trolled environment, with a 12 h light:dark cycle with food and water available ad
libitum. Play tunnels and bedding material were used to provide environmental
enrichment. In addition to the standard weight and health checks performed by
researchers, animals were monitored at least once daily by a trained animal
technician to ensure that they were in good health. Mice were randomized between
the different treatment groups for each experiment and were observed regularly
during the study. Mice used were either naive or treated with a single orophar-
yngeal 50 µl dose (1 mg/kg or 3 mg/kg) of bleomycin sulfate (Bleo-Kyowa; Aesica
Queenborough Ltd, Kent, UK) or saline vehicle.
In prophylactic studies s.c. osmotic mini-pumps (ALZET® mini-osmotic pump
model 2004) were surgically implanted 3 days prior to bleomycin dosing and
GSK3008348 in sterile saline was administered at a dose of 15 mg/kg/day for
14 days post bleomycin instillation. For therapeutic dosing studies, mice were
dosed twice daily by i.n. inhalation of 3 mg/kg GSK3008348 from day 14 to day 28
post bleomycin instillation (3 mg/kg).
In bleomycin studies assessing the effect of single doses of compound on PD
biomarkers, 1 mg/kg GSK3008348 in sterile saline was administered via the i.n.
route (50 µl administered equally between nostrils to mimic its intended clinical
dose route) either 7, 14, or 28 days post bleomycin instillation. In single-dosing
studies measuring Smad2 levels in lung tissue and BAL cells, SB-525334 (TGFβR1
inhibitor) was dosed via oral gavage at 30 mg/kg (0.2% (v/v) Tween 80 in saline,
adjusted to pH 4.1 with NaOH) at day 14 post bleomycin instillation, with sample
collection completed 2 h post dosing.
At the end of studies, mice were culled by an overdose of pentobarbitone
sodium (Euthatal; Merial Animal Health Ltd, Essex, UK) and death confirmed by
the permanent cessation of circulation and/or dislocation of the neck as
appropriate. At the defined time points post dosing detailed in the “Results”
section, the following samples were collected as applicable to each study. Where
BAL cells and BALF were required, samples were collected by slowly aspirating and
withdrawing 0.5 ml PBS into the trachea using a flexible butterfly catheter. This was
repeated three times and BAL fluid (total ~1.5 ml) was pooled, treated with 15 µL
protease and phosphatase inhibitors and kept on ice. An aliquot of BAL fluid was
used to perform a total cell count. The remaining BAL fluid was centrifuged (150 ×
g for 10 min at 4 °C) and the cell pellet and BAL supernatant stored separately at
−80 °C. Lungs were removed, snap frozen, and ground to powder under liquid
nitrogen, divided into two aliquots and processed for measurement of pSmad2 and/
or hydroxyproline. In animals that had undergone BAL sample collection, the lung
samples for hydroxyproline analysis was dried at 60 °C for 2 h prior to processing
otherwise the lung samples were processed for the analysis of hydroxyproline
levels. For hydroxyproline assays, the lung powder was mixed in 1 ml distilled
water on ice in Pyrex tubes and incubated in 125 μl 50% TCA (Sigma-Aldrich,
Gillingham, Kent, UK) at 4 °C for 20 min. Samples were centrifuged at 528 × g for
10 min at 4 °C, hydrolyzed in 1 ml of 12 N HCL overnight at 110 °C prior to
reconstitution in 2 ml of distilled water. In total, 200 μl of hydrozylate, or
hydroxyproline standard, were oxidized in 500 μl chloramine T for 20 min at room
temperature (20–22 °C) prior to the addition of 500 μl of Ehrlich’s solution and
incubation at 65 °C for 15 min. Samples were then incubated at room temperature
for 2 h prior to colorimetric analysis at an absorbance of 550 nm. Hydroxyproline
per mg of lung tissue was calculated against a standard curve.
The remaining aliquot of lung powder was lysed in Cell Lysis Buffer (Cell
Signaling Technology, MA, USA) containing protease and phosphatase inhibitors
(Halt™ protease and phosphatase inhibitors cocktail (Thermo Fisher Scientific, MA,
USA)) according to the manufacturer’s instructions. For animals requiring
histological end point analysis, lungs were insufflated with 10% formalin (VWR
chemicals, UK) at constant gravitational pressure (20 cm H2O) then paraffin wax
embedded for histology.
Where applicable, a blood sample from each animal was taken via cardiac
puncture and split between containers with or without anti-coagulant (lithium
heparin) to permit both for PK and PD analysis. The concentration of parent
compound in blood was determined by reverse phase HPLC/MS/MS using an
electrospray ionization interface in positive ion mode against a matrix matched
calibration line. The lower limit of quantitation in blood of GSK3008348 was 2 ng/
ml. The serum levels of the MMP-degraded ECM protein C3M was determined in
a competitive ELISA-based, neoepitope assay manufactured by Nordic Bioscience
(Herlev, Denmark) and performed according to the manufacturer’s specifications.
In brief, 96-well pre-coated streptavidin plates were coated with biotinylated
peptides specific for the protein of interest and incubated for 30 min at 20 °C. A
volume of 20 μl of standard peptide or pre-diluted serum sample were added
followed by addition of peroxidase-conjugated monoclonal antibodies and
incubated for 1 h at 20 °C. Next, tetramethylbenzinidine (TMB) (Kem-En-Tec
Diagnostics, Denmark) was added and the plates were incubated for 15 min at 20 °
C. All incubations included shaking of the plates followed by five washes with
buffer (20 mM Tris, 50 mM NaCl, pH 7.2). The reaction of TMB was stopped by
adding 1% sulfuric acid and the absorbance was measured at 450 nm, with 650 nm
as reference. A standard curve was plotted using a four-parametric mathematical fit
model and data were analyzed using the Softmax Pro (version 6.3) software. Levels
of the biomarkers were measured in duplicates.
Mice undergoing nanoSPECT-CT imaging were injected intravenously via the
tail vein with 15–30MBq of 111In-labeled DTPA-A20FMDV2 peptide in sterile
water using a 50 µl dose volume 1 h prior to scanning. Mice were anaesthetized by
exposure to isofluorane (3%), transferred to the sealed CT/SPECT tube and
maintained under anesthesia at 1% isofluorane for the duration of the scan (45 min
in total) at an oxygen flow rate of 1 L/min. Whole-body helical CT and SPECT
scans were performed with a nanoSPECT-CT imaging system (Bioscan Inc,
Washington, DC) fitted with four tungsten collimators and nine 1.4 mm diameter
pinholes. SPECT images were obtained 2 h (saline/GSK3008348) or 24 h (IgG
isotype control/10D5 anti-αvβ6 antibody intra-peritoneal administration in PBS at
2.5 mg/kg (Merck Millipore, Billerica, MA, USA)) post dosing of test agents with a
time per view of 60 s resulting in a scan time of 30–45 min. CT images were
obtained using a tube voltage of 45 kVp and an exposure time of 500 ms per view22.
Lung histology. Histological sections of murine lung were cut at three microns and
dewaxed in xylene prior to rehydration in decreasing concentrations of ethanol.
The sections were incubated in either Mayer’s haemotoxylin, and eosin or Sirius
red and Weigert’s haemotoxylin. Tissue staining was imaged using Nikon Eclipse
90i microscope and NIS Elements AR3.2 software (Nikon).
Ex vivo human studies. Human fibrotic lung tissue was collected from human
explants after transplantation. Tissue which the pathologist deemed suitable for
research was inflated with 2–3% low boiling point agarose, with the agarose being
allowed to set at 4 °C. PCLS were then cut at 400 μm on a vibrating microtome and
cultured in DMEM media. PCLS were rested for 48 h prior to treatment. PCLS
were incubated with inhibitors for 48 h prior to tissue slices being lysed in 1x Cell
Lysis Buffer (Cell Signaling Technology, MA, USA) containing protease and
phosphatase inhibitors (Halt™ protease and phosphatase inhibitors cocktail
(Thermo Fisher Scientific, MA, USA)) according to the manufacturer’s
instructions.
BAL cell and fluid samples were obtained from patients undergoing routine
diagnostic BAL. BALF cell pellets were prepared by centrifugation (300 × g for 5
min) and differentially counted. Following re-suspension cells were incubated in
RPMI containing 0.1% DMSO (vehicle control) or inhibitor (30 min at 37 °C in
95%:5% air:CO2). Following incubation, suspensions were centrifuged (300 g for 5
min) and cell pellets lysed in ice cold PhosphoSafe® buffer (Merck Millipore)
before being assayed for pSmad2 and total Smad.
Statistical analysis. Statistical analyses were completed using GraphPad Prism 7.0
(GraphPad Software, San Diego, CA, USA) for in vitro studies and R version 3.4 for
in vivo/ex vivo studies. Statistical significance between two data sets was tested
using a Student’s unpaired t test. One-way analysis of variance was used for
comparison of more than two data sets and, where significance was observed, an
appropriate post test completed. Unless otherwise indicated data shown graphi-
cally, and in the text, are either mean ± standard deviation or, where three or more
data points/individual experiments have been completed, mean ± standard error of
the mean.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available
within the paper and its supplementary information files. Source data are provided with
this paper.
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